Show simple item record

dc.contributor.authorÖmür, Özgür
dc.contributor.authorBaran, Yusuf
dc.date.accessioned2017-04-26T07:30:58Z
dc.date.available2017-04-26T07:30:58Z
dc.date.issued2014-01
dc.identifier.citationÖmür, Ö., and Baran, Y. (2014). An update on molecular biology of thyroid cancers. Critical Reviews in Oncology/Hematology, 90(3), 233-252. doi:10.1016/j.critrevonc.2013.12.007en_US
dc.identifier.issn1040-8428
dc.identifier.urihttp://doi.org/10.1016/j.critrevonc.2013.12.007
dc.identifier.urihttp://hdl.handle.net/11147/5405
dc.description.abstractDifferentiated thyroid cancer (DTC) is the most common endocrinological malignancy. There are several histological variants such as papillary and follicular thyroid carcinoma. Many patients with well-differentiated subtypes of DTC are cured by surgery alone or with radioiodine, while poorly differentiated types usually have a worse prognosis. The aggressiveness of thyroid tumors is closely linked to specific gene alterations.Several diagnostic and prognostic molecular markers such as BRAF and RAS point mutations; RET/PTC and PAX8/PPARγ gene rearrangements; MAPK, PI3K, p53, Wnt-beta catenin, HIF1α and NF-kappaB signaling pathways; microRNA profiles and aberrant methylation have been demonstrated in more than 70% of DTC. Diagnostic use of these molecular markers may be optimized for identifying higher risks of mortality, tumor recurrence and metastatic potential. Understanding the molecular biology of thyroid cancers can be an important avenue for diagnosis and treatment of radioiodine-refractory or inoperable DTC patients with novel molecular targeted therapeutic agents. © 2014 Elsevier Ireland Ltd.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.isversionof10.1016/j.critrevonc.2013.12.007en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBRAFen_US
dc.subjectDifferentiated thyroid canceren_US
dc.subjectThyroid canceren_US
dc.subjectRET/PTCen_US
dc.subjectPAX8/PPARγen_US
dc.subjectTumor markersen_US
dc.titleAn update on molecular biology of thyroid cancersen_US
dc.typereviewen_US
dc.contributor.authorIDTR119193en_US
dc.contributor.iztechauthorBaran, Yusuf
dc.relation.journalCritical Reviews in Oncology/Hematologyen_US
dc.contributor.departmentİYTE, Fen Fakültesi, Moleküler Biyoloji ve Genetik Bölümüen_US
dc.identifier.volume90en_US
dc.identifier.issue3en_US
dc.identifier.startpage233en_US
dc.identifier.endpage252en_US
dc.identifier.wosWOS:000337774900005
dc.identifier.scopusSCOPUS:2-s2.0-84899917464
dc.relation.publicationcategoryDiğeren_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record